In light of the evidence that the GG-genotype of rs5050 is linked to the lower AGT expression, and that the lower AGT expression, in turn, is related to longer survival particularly in these GBM subjects with anti-VEGF treatment, we might hypothesize for future studies a plausible role of AGT rs5050 as a potential biomarker of BVZ response. The gene discussed is AGT; the disease is glioblastoma.